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ALLERGIC rhinitis is a condition which affects over 15%
of the population in the United Kingdom. The patho-
logical process involves two stages: nasal inflamma-
tion,  and  the  development  of  nasal  airway  hyper-
responsiveness  (AHR)  to  allergen  and  a  number  of
other stimuli. This results in the amplification of any
subsequent  allergic  reaction,  contributing  to  the
chronic allergic state. A number of different hypoth-
eses have been proposed to explain the underlying
mechanism of AHR, including a role for eosinophil-
derived  proteins,  free  radicals  and  neuropeptides.
While there may be a number of independent path-
ways  which  can  result  in  AHR,  evidence  obtained
from both animal models and in vivo experiments in
humans  indicate  that  some  mediators  may  interact
with one another, resulting in AHR. Further research
into these interactions may open new avenues for the
pharmacological treatment of chronic allergic rhini-
tis, and possibly other allergic airway diseases.
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Introduction
Allergic  rhinitis  and  asthma  are  two  of  the  most
common immunological disorders producing chronic
disease in man. For instance, allergic rhinitis affects
over 15% of the general population.1 In both diseases,
a  local  allergic  reaction  results  in  an  inflammatory
response, causing wheezing and mucus secretion in
asthma,  and  nasal  congestion,  rhinorrhoea  (‘runny
nose’), pruritis (itching) of the nose and sneezing in
allergic  rhinitis.  Continued  exposure  to  allergen
induces  a  state  of  chronic  allergic  inflammation.
Contributing  to  this  is  the  development  of  airway
hyperresponsiveness  (AHR),  which  results  in  the
amplification of any subsequent allergic reaction.
While a variety of pharmacological agents can be
used to treat the initial inflammatory response, only
steroids are effective in preventing AHR. The mecha-
nism  by  which AHR  occurs  remains  unclear.  If  the
mechanism of AHR can be described, then this may
provide  new  pharmacological  targets  for  the  treat-
ment of chronic allergic airway disease. While allergic
rhinitis is not life-threatening, the same is not true for
chronic asthma, and the problem is compounded by
the adverse effects associated with long-term steroid
use.
Unfortunately, animal models and in vitro experi-
ments  are  of  limited  value,  since  they  are  not
representative  of  the  situation  in  man.2,3 However,
the human nasal airway is reasonably accessible for in
vivo research into the development of nasal AHR, and
may also yield some insight into the mechanism of
AHR in asthma. We review here current hypotheses
for the development of AHR in the human nose, and
indicate  potential  new  pharmacological  targets  for
the treatment  of allergic rhinitis and possibly other
allergic airway diseases.
Pathogenesis  of  allergic  rhinitis
There  are  two  distinct  forms  of  allergic  rhinitis,
depending  on  the  allergen  to  which  the  subject  is
sensitive.  In  perennial  allergic  rhinitis  (PAR),  the
subject is  exposed  to  allergen  throughout the year,
while in subjects with seasonal allergic rhinitis (SAR),
allergen exposure is limited to certain times during
the year. Subjects with PAR are sensitive to allergens
including those from the house-dust mite (Dermato-
phagoides  pteronyssinus ), other  mites,  animal  dan-
ders  and  certain  foods.  In  contrast,  the  allergens
involved in SAR are tree and grass pollens, moulds and
certain fungal spores.
Nasal  inflammation
When particles of allergen are inhaled into the nasal
cavity, they cross the nasal mucosa and are exposed to
the  immune  system; in  susceptible  individuals,  this
results in sensitisation, a process where immunoglo-
bulin  E  (IgE)  is  synthesised  and  becomes  fixed  to
cells, such as mast cells. If these cells subsequently
encounter  the  same  allergen,  crosslinking  occurs
between IgE molecules on the cell surface, causing
the  release  of  inflammatory  mediators  including
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shown in Table 1. These mediators are responsible for
the  symptoms  of  allergic  rhinitis.  Nasal  blockage
results from a combination of increased blood flow to
the nose (causing swelling of the nasal tissue), plasma
extravasation,  and  oedema.  Rhinorrhoea  is  a  con-
sequence of the stimulation of nasal secretory glands,
which  produce  a  mixture  of  watery  or  serous
secretion  and  viscous  mucus  secretion,  mixed
together  with  extravasated  plasma.  Stimulation  of
sensory nerves in the nasal cavity causes sneezing and
pruritis.
One  method  used  to  study  the  inflammatory
response in the human nose is nasal lavage, where the
nasal cavity is rinsed with a solution (such as saline),
and  the  lavage  fluid  subsequently  collected  and
analysed. Using  this  technique,  one  can  measure  a
number of inflammatory mediators using appropriate
assays. Furthermore, by collecting and counting cells
present in the lavage fluid, it is possible to correlate
the  release  of  inflammatory  mediators  with  the
different cells observed.
The response  of  subjects with  allergic rhinitis to
intranasal  challenge  can  often  be  divided  into  an
immediate  phase,  occurring  during  the  first  2 h
following exposure to antigen, and, in about 30–40%
of subjects, a late phase occurring 6–12 h later. The
late  phase  is  associated  with  an  infiltration  of  a
number  of  different  inflammatory  cells  (including
eosinophils,  neutrophils  and T-lymphocytes)  to  the
site of inflammation, where they release a variety of
mediators  including  leukotrienes,  cationic  proteins
such as eosinophil cationic protein (ECP), and cyto-
kines (Table 1).
Interestingly,  there  may  be  differences  in  the
precise  mediators  involved  in  PAR  and  SAR. While
histamine is strongly associated with the early phase
of SAR, histamine H1 antagonists are not very effective
in  reducing  the  early  allergic  response  of  PAR.
Instead, the kinins appear to be the major mediator
causing symptoms in PAR.5 There is also evidence that
the allergen (house dust mite) in PAR can generate
kinin  independent  of  the  inflammatory  response,
either  by  the  direct  activation  of  kallikrein,  the
enzyme  which  generates  kinins,6 or  by  possessing
such biochemical activity itself.7
Nasal  airway  hyperresponsiveness
Nasal  hyperresponsiveness  is  a  hallmark  of  allergic
rhinitis.8,9 Subjects  with  allergic  rhinitis  show  an
increased response to nasal challenge with a variety of
stimuli, including histamine and bradykinin, both of
which are released following allergen challenge. The
nasal  airway  effectively  becomes  more  sensitive  to
allergen,  contributing  to  the  chronic  allergic  state.
AHR is usually associated with the late phase reaction,
but can continue well beyond this stage. In fact, it is
induced  irrespective  of  whether  a  late  phase  of
inflammation occurs.10
One  important  consideration  is  the  type  of
response  involved in AHR. In  asthma, AHR  is  often
defined as an increase in the contractile response of
the  airway  smooth  muscle.  However,  there  is  little
smooth  muscle  present  in  the  human  nasal  airway.
Nasal blockage results from increased blood flow to
the nasal mucosa, and not by an action  on smooth
muscle. This highlights the difficulty of extrapolating
data from the nasal airway to the lower airways, and
vice  versa.  AHR  is  also  associated  with  increased
mucus  production  and  oedema  following  allergen
challenge,  in  both  the  upper  and  lower  airways.
Therefore, AHR would appear to result from a direct
or  indirect  potentiation  of  the  overall  receptor
activation,  and  not  simply  from  an  action  on  a
particular cell type alone. With this in mind, there are
a  number  of  potential  mechanisms  by  which AHR
might occur (Fig. 1).
(1) The inflammatory cascade:
Initial  exposure to  allergen  might trigger  a  cascade
reaction,  causing  increased  mediator  release  and,
therefore,  greater  receptor  activation.  For  instance,
subjects  with  SAR  experience  increasingly  severe
symptoms as the pollen season continues. However, a
number of inflammatory mediators can induce AHR in
the absence of any other mediator. Furthermore, the
development  of AHR  can  occur  independently  of  a
chronic  inflammatory  response.10 It  is  likely,  there-
fore,  that  the  AHR  potentiates  the  effect  of  the
inflammatory cascade seen in chronic allergic rhinitis,
rather than being caused by it.
(2) Increased exposure of receptors on the nasal
mucosa to the stimulus:
A  common  histological  finding  in  chronic  airway
allergy is the damage and shedding of epithelial cells
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Table 1. Mediators found in nasal lavage fluid collected
following both the immediate  and late phase response in
atopic  individuals  challenged  intranasally  with  allergen
4
Mediator Immediate
phase
Late
phase
Histamine 33 33
TAME-esterase 33 33
Prostaglandin  D2 33 7
Leukotrienes  LTB4/C4/D4 3 3
Kinins 33 3
Platelet-activating  factor  (PAF) 3 7
Albumin 33 33
Neuropeptides,  e.g.  CGRP  and  VIP 3 7
Substance  P 3 3
Eosinophil-derived  mediators,
e.g.  ECP,  MBP
7 33
Interleukin  1  (IL-1) 3 3
IL-3,  IL-4,  IL-5,  IL-6,  TNFa 7 3lining the airway. The airway epithelium can act as a
physical barrier between the airway lumen and the
underlying mucosa. Therefore, removal of these cells
would increase the exposure of the receptors on the
mucosa to any stimulus present. For example, in the
lower  airways,  removal  of  the  airway  epithelium
increases  the  response  of  smooth  muscle  in  both
animal models and human bronchi ex vivo.11 While
there may be a link between epithelial shedding and
the presence of AHR in allergic individuals,12 media-
tors which induce AHR on their  own (e.g. platelet-
activating factor) do not cause epithelial shedding in
the time taken for AHR to develop, though the doses
required are toxic to airway epithelial cells.13 Alterna-
tively, the loss of airway epithelial cell function, but
not necessarily barrier function, may be sufficient to
induce AHR.14 In  the  human  nasal  airway, AHR  to
bradykinin  is  unlikely  to  be  due  to  a  reduction  in
epithelial barrier function,15 and there is no evidence
for increased epithelial permeability in subjects with
allergic  rhinitis.16 Mediators  such  as  PAF  may  also
damage the mucociliary  clearance  system linked to
the airway epithelium, contributing to the AHR.13
(3) Modulating agents:
The ability of acetylcholine to cause vasodilatation in
the vascular system is dependent upon the release of
nitric oxide from the endothelium (and possibly other
mediators,  collectively  known  as  endothelium-
derived relaxing factors). It has been proposed that
airway epithelial cells may generate mediators, such
as arachidonic acid metabolites, nitric oxide and the
putative epithelium-derived  relaxing  factor (EpDRF)
(also  known  as  EDHF  (epithelium-derived  hyper-
polarsing factor)) which modulate the responsiveness
of  the  airways.  However,  the  evidence  for  such
mediator release from airway epithelial cells is equiv-
ocal.11,17–19 The  epithelium may have  an  important
role in the metabolism of various stimuli, particularly
adenosine,20 tachykinins18 and acetylcholine.21 Loss
of epithelial cell function might reduce the metabo-
lism  of  these  mediators,  enhancing  their  ability  to
activate  receptors  and  effect  a  response.  However,
epithelial damage can occur without the presence of
AHR, and vice versa.22 For example, cationic proteins
can cause AHR without any apparent damage to the
epithelium.23
(4) Receptors:
AHR may result from a change in the characteristics of
receptors located on the nasal mucosa. For example,
cholinergic agonists such as methacholine cause more
secretion  in  allergic  subjects  than  in  non-allergic
controls, and this could be explained by an increase
in  the  density  of cholinergic  receptors.24 However,
the  density  of muscarinic receptors  on  nasal tissue
from allergic subjects may actually decrease slightly,
possibly  as  a  result  of  adaptation  due  to  over-
stimulation, although the remaining receptors exhibit
an increased affinity, which might contribute to the
hypersecretion.25 No  significant  differences  have
been  found  for a - or  b -adrenoceptors.26 The  minor
changes observed are probably a result, rather than
the cause, of AHR.
(5) Metabolism:
Alternatively, AHR may be a consequence of prolonged
activity of a variety of mediators, due to an effect on
their  metabolism.  For  example,  neuropeptides  are
degraded  by  neutral  endopeptidase  (NEP),  and  the
activity of NEP is significantly lower in subjects with
nasal  AHR.27 A  second  protein,  lactoferrin,  may
prevent antigen-induced AHR in the lower airways of
sheep by inhibiting tryptase.28Though the precise role
of tryptase in airway allergy is not fully known, it can
induce AHR in the lower airways of sheep29 and in ex
vivo tissue from human bronchi.30
(6) Altered intracellular signalling:
Finally, the intracellular pathways which are activated
by  the receptor/agonist  complex may be altered in
AHR. Of  particular interest is phosphodiesterase IV
(PDE4), an enzyme which catalyses the metabolism of
a number of intracellular messengers, such as cyclic
GMP (cGMP). While PDE4 inhibitors abolish AHR in
animal  models,31 the  data  in  human asthmatic  sub-
jects  are  equivocal,32 and  there  are  no  data  with
respect  to  the  human  nasal  airway.  Interestingly,
inhibitors of nitric oxide synthase can also cause AHR,
possibly  by  reducing  the  amount  of  cGMP.33 AHR
could result from a loss of a compensatory mecha-
nism, involving cGMP; such a mechanism may be free
radical dependent.34 In the chronic allergic state, AHR
Nasal airway hyperresponsiveness
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FIG. 1. Potential  mechanisms in the development  of AHR.
¶ Inflammatory  Cascade;  · altered  exposure  of  the  receptor
to  the  stimulus;  ¸ release  of  modulating  agent  by  other  cells;
¹ change  in  the  receptor  properties;  º altered  metabolism  of
the  mediator;  » altered  regulation  of  the  intracellular  signal-
ling  resulting  in  the  response.may result, in part, from a change in gene transcrip-
tion within cells (e.g. the NF-kB transcription system),
though the timescale of onset of hyperresponsiveness
makes this process unlikely in the induction of AHR.
Mediators  implicated  in  the  development
of  AHR
In 1933, Sir Henry Dale described a number of criteria
which should be used to identify potential inflamma-
tory mediators. Applying these to the development of
AHR:
d administration  of  the  potential  mediator  should
cause AHR in vitro and in vivo;
d the  mediator  should  be  present  in  appropriate
concentrations in allergic individuals with AHR;
d the mechanisms involved in the generation of the
mediator  should  be  present  and  increased  in
AHR;
d a mechanism should exist to terminate the action
of  the  mediator  (important,  because  AHR  is  a
reversible phenomenon);
d antagonists of the mediator reduce the induction of
AHR;
d receptors/signalling pathways should be present in
the  nasal  mucosa,  and  be  activated  by  the
mediator.
The process by which AHR occurs remains unclear,
no  doubt  due,  in  part,  to  the  complexity  of  the
mechanism and the difficulty in regulating the proc-
ess under controlled experimental conditions. None-
theless,  because  it  is  associated  with  the  influx  of
cells  to  the  site  of  inflammation,  a  number  of
hypotheses have been proposed involving mediators
released from these cells. One particular cell type, the
eosinophil, has been implicated in AHR. In both SAR
and PAR, antigen challenge results in an increase of
eosinophils  in  the  nasal  mucosa  and  the  release  of
various  eosinophil-derived  mediators.35 –39 Conse-
quently a major role has been proposed for eosino-
phils and their proteins in this process.
Eosinophil  granule-derived  proteins
Eosinophils contain granules composed of four basic
proteins. The  core  of  these  granules  is  major  basic
protein (MBP), while the matrix surrounding the core
is  composed  of  eosinophil  cationic  protein  (ECP),
eosinophil-derived neurotoxin (EDN) and eosinophil
peroxidase  (EPO).40 The  possible  roles  of  these
proteins  in  allergic  airway  disease  are  described  in
Table 2.
The  levels  of  ECP,  EPO  and  MBP  are  raised
following antigen challenge in allergic rhinitis,37–39,41
and these increases often coincide with the presence
of AHR. MBP and other cationic proteins, including
the synthetic protein poly-L-lysine, cause AHR in the
lower airways of rats,23 which appears to be depend-
ent on their cationic charge. However, no study has
yet  been  conducted  to  investigate  whether  these
cationic proteins can themselves induce AHR in the
human nasal airway.
The mechanism of MBP-induced AHR is unknown,
though  it  may  be  dependent  on  causing  epithelial
damage, since MBP only induces AHR in guinea pig
tracheal  preparations  with  an  intact  epithelium.42
However,  as  stated  above,  cationic  proteins  may
induce  AHR  without  causing  epithelial  damage.23
Furthermore,  although  all  the  eosinophilic  cationic
proteins  are  cytotoxic  to  the  airway  epithelium,43
only MBP caused AHR in a study on primates.44 In the
lower airway of the rat, AHR induced by MBP or poly-
L-lysine is abolished by both neurokinin NK-145 and
bradykinin  B246 antagonists,  indicating  a  role  for
substance  P  and  the  kinins  in  the  development  of
AHR.  It  is  also  possible  that  eosinophil  cationic
proteins act on other inflammatory cells to generate
the  conditions  required  for  AHR.22 While  there  is
evidence  for  a  relationship  between  ECP  levels  in
nasal lavage and nasal AHR,47 this has not always been
reproduced in other studies,48,49 so ECP is unlikely to
be solely responsible for the induction of nasal AHR.
Platelet  activating  factor  (PAF)
PAF is a naturally occurring phospholipid, and is the
only endogenous compound known to induce AHR in
both  animals  and  man.50 In  normal,  non-atopic
subjects,  it  induces  a  nasal  AHR  to  histamine  and
bradykinin51,52 and causes an increased response to
pollen in subjects with SAR.51 The resulting AHR is
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Table  2.  Cationic  proteins  found  in  eosinophil  granules
40
Protein Cell  content
(m g/10
6 cells)
Role  in  allergic  airway  disease
MBP 9 d causes  histamine  release  from
basophils  and  mast  cells
d cytotoxic  for  human  epithelial
cells
d causes  bronchoconstriction  and
induces  hyperresponsiveness  in
animals
d activates  neutrophils
ECP 5 d causes  histamine  release  from
mast  cells
d cytotoxic  to  a  variety  of  cells
EDN 3 d undefined
EPO 12 d cytotoxic  to  airway  epithelium
d provokes  bronchoconstriction
in  animals
d in  the  presence  of  H2O2 and
halide,  causes  mast  cell
degranulation  and  histamine
release  and  inactivates
leukotrienessimilar,  in  many  ways,  to  that  observed  in  allergic
rhinitis,  as  PAF  also  causes  a  significant  nasal  neu-
trophilia and eosinophilia, together with raised ECP
levels in nasal lavage fluid.52 –54
Although PAF can induce AHR in the human nasal
airway, its role in allergen-induced AHR is less defined.
Antigen challenge with grass pollen in atopic individ-
uals  with  SAR  causes  the  release  of  lyso-PAF  and
PAF,41,55 but it is unclear whether PAF or lyso-PAF are
released  in  PAR,56 One  possibility  is  that  any  PAF
generated is converted to lyso-PAF by acetylhydrolase
present in the lavage fluid. The activity of this enzyme
in  lavage fluid is significantly raised following grass
pollen challenge in sensitive subjects.41,57
PAF  may  act  directly  on  the  nasal  mucosa,  and
radioligand binding studies indicate the presence of
specific binding sites for PAF in human lung tissue,58
but no such studies have yet been performed using
tissue  obtained  from  the  human  nose.  One  of  the
main features of PAF is its ability to attract and activate
a variety of inflammatory cells, including eosinophils,
neutrophils, monocytes, macrophage and platelets.50
PAF  may  also  release  from  airway  epithelial  cells  a
range  of  chemotactic  factors  for  neutrophils  and
eosinophils,  including  the  cytokine  GM-CSF .59 The
subsequent  activation  of  these  cells  will  release  a
range of mediators which can act on other cells in the
airway. Administration  of  PAF  into  the  nasal  airway
also causes ECP release, which could then contribute
to the AHR.52,53
If PAF is an important mediator of nasal AHR, one
would  expect  PAF-antagonists  to  reduce  leukocyte
infiltration  and  inhibit  antigen-induced AHR. While
this effect has been observed in some studies using
animal models,60–62 the PAF antagonists WEB 208641
and UK 74,50563 did not alter AHR in the human nasal
airway. However, both these antagonists exhibit a low
potency for PAF receptors, and may cause only a weak
inhibitory action in man.
PAF  causes  mucosal  dysfunction  and  damage,
inhibiting ciliary action and increasing exfoliation of
the epithelial lining of the airway both in vivo in the
lower  airways  of  the  rabbit13 and  in  vitro using
explants  from  human nasal  mucosa.64 Interestingly,
the latter study found that PAF is itself cytotoxic to
epithelial cells, without requiring the production of
other  cytotoxic mediators.  PAF-induced AHR in  the
human nasal airway was almost abolished by pretreat-
ment  with  the  antioxidant  vitamin  E,52 implying  a
mechanism which is dependent on the generation of
free radicals. This supports the hypothesis that  PAF
causes tissue damage which may be independent of
the  release  of  other  mediators,  perhaps  via  the
generation  of  free  radicals. The  source  of  the  free
radicals could be the epithelial cells, so in effect, the
epithelium may cause its own destruction.65
It is unclear, however, whether sufficient quantities
of PAF are produced in the antigen-induced allergic
response  to  cause  AHR,  and  there  are  probably
differences  in  the  underlying  mechanism  of  AHR
induced by PAF and antigen.
Leukotrienes
The  leukotrienes  are  generated  by  the  action  of
5-lipoxygenase on arachidonic acid. They are released
in  both the early and late phases following  antigen
challenge in subjects with SAR66 and during the early
phase in PAR.67 There are two classes of leukotrienes:
LTB4 and  the  peptidyl-cysteinyl  leukotrienes  (LTC4,
LTD4 and LTE4). The latter group are synthesised by
eosinophils  (among  other  cells)  and  cause  a  long-
lasting eosinophilic infiltration, and have been asso-
ciated with AHR in the lower airways in rats68 and in
man;69 both these actions appear to be dependent on
eosinophil  activation. Although  inhibitors  of  leuko-
triene  synthesis  reduce  the  nasal  blockage  experi-
enced  following  challenge  with  grass  pollen  in
allergic subjects,70,71 no studies have investigated the
effect  of  such  drugs  on  AHR  in  the  human  nasal
airway,  though  zileuton,  a  lipoxygenase  inhibitor,
reduced antigen-induced AHR in the lower airways of
asthmatics.72 Pharmacological  intervention  can  also
be achieved at the level of the receptor, and a number
of leukotriene receptor antagonists have been devel-
oped which inhibit AHR in animal models.73 Many of
these  are  currently  under  study  in  man,  including
pranlukast, which may reduce AHR in  asthmatics,74
and montelukast, which has recently been approved
for use in the USA. The role of LTB4 in AHR is not clear,
but  LTB4 antagonists  have  been  shown  to  inhibit
antigen-induced  AHR  in  the  lower  airways  of  pri-
mates75 and  the  guinea  pig.76 Although  human
eosinophils cannot produce LTB4 because they lack
the  enzyme needed for its synthesis, it  is  the main
lipoxygenase  product  in  neutrophils,  and  acts  as  a
potent  stimulus  for  leukocyte  infiltration  and  sub-
sequent degranulation.77
Prostaglandins  and  thromboxanes
The  prostaglandins  PGD2 and  PGE2 are  detected at
increased levels in nasal lavage fluid following aller-
gen challenge in subjects with SAR78,79 and PAR,80 but
only in the early response and not the late phase of
inflammation.66 Inhibitors  of  cyclooxygenase,  the
enzyme required for the synthesis of prostaglandins,
do not affect the response to antigen in the human
nasal  airway.66 PGE2 is  synthesised  by  the  airway
epithelium  and  has  been  proposed  as  a  possible
EpDRF .  In  the  lower  airways, AHR  may  result  from
epithelial  damage,  reducing  PGE2 generation  by
epithelial cells and, therefore, decreasing its relaxant
effect on airway smooth muscle.81 However, in  the
human nose, any action of PGE2 would presumably
have to be on blood vessels (since there is little airway
Nasal airway hyperresponsiveness
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also  expect  a  decrease  in  PGE2 release  if  it  was
involved in AHR, yet the opposite is true. Thrombox-
ane A2 (TxA2) does appear to mediate AHR in animal
models82,83 and may do likewise in man.84 Inhibition
of  thromboxane  synthesis  reduces  AHR  and  also
inhibits airway eosinophilia after allergen challenge.85
The thromboxanes may, therefore, have an important
role  in  upregulating  the  eosinophil-associated
response.77 The  contribution  of  thromboxanes  to
nasal allergy remains undefined, and more research is
needed  to  investigate  their  potential  role  in  the
development of AHR.
Neuropeptides
Sensory  nerve  fibres  contain  a  number  of  different
peptides,  including  calcitonin  gene-related  peptide
(CGRP) and the tachykinins substance P (sub P) and
neurokinin A (NK-A). These neuropeptides, metabo-
lised inter alia by the enzyme neutral endopeptidase
(NEP), are released from sensory nerves which form
part  of  the  non-adrenergic  non-cholinergic  (NANC)
nervous system, and are capable of generating a local
axon  reflex  which  causes  an  increase  in  vascular
permeability,  plasma  leakage  and  subsequent  tissue
oedema.  This  response  is  known  as  neurogenic
inflammation, and is mediated by the tachykinin NK-1
and  NK-2  receptors.  In  addition,  eosinophils  are
capable  of  producing  vasoactive  intestinal  peptide
(VIP) and sub P.86 All these neuropeptides are found in
nasal secretions following nasal challenge with grass
pollen,87 but  their  role  in  AHR  remains  unclear.
However, there is a correlation between the presence
of AHR and the activity of NEP in the human nose.27
Furthermore, in both PAR and SAR, AHR to bradykinin
is  mediated  by  neural  reflexes,15 which  could con-
ceivably include a role for neuropeptides.
Neuropeptides appear to be important  in AHR in
a  variety  of  animal  models.  In  the  lower  airway  of
the rat, AHR induced by eosinophil-derived cationic
proteins  is  inhibited  by  neurokinin  NK-1  receptor
antagonists and capsaicin.45 In the guinea pig, appli-
cation  of  capsaicin  to  the  lower  airway  (an  action
which  depletes  sensory  nerves  of  neuropeptides)
also abolishes antigen-induced AHR.88,89 The tachyki-
nins,  particularly  sub  P,  may  enhance  eosinophil
recruitment90,91 and,  therefore,  cause  AHR  via  an
eosinophil-dependent  mechanism.  However,  the
inhibition  of  AHR  by  capsaicin  does  not  affect
lipoxygenase  activity  or  eosinophil  infiltration,  sug-
gesting that neuropeptides cause AHR independently
of,  or  after,  eosinophil  activation  and  leukotriene
synthesis.89
Neurogenic inflammation may be a phenomenon
only  found  in  animals,  since  one  study  found  no
evidence of capsaicin-induced neurogenic inflamma-
tion  in  the  human  nasal  airway.92 However,  other
studies,  some  utilising  higher  doses  of  capsaicin,
confirm that neurogenic inflammation does occur in
allergic rhinitis.93,94 Furthermore, application of cap-
saicin  reduces  the  symptoms  caused  by  antigen
challenge  in  SAR95 and  PAR96,  though  neither  of
these studies investigated AHR. It is, therefore, possi-
ble that AHR in the human nasal airway may result,
at least in part, from an upregulation of neurogenic
inflammation,  possibly  due  to  epithelial  damage
increasing the exposure of sensory nerves. Bradyki-
nin  causes  neuropeptide  release  in  vivo in  the
human nasal mucosa,97 while histamine has a similar
effect  on  human  lung  tissue  ex  vivo.98 Damage  to
the  airway  epithelium  may  increase  exposure  of
sensory  nerves  to  stimuli,  effectively  causing  an
upregulation  of  neurogenic  inflammation.  This
would  result  in  increased  neuropeptide  release,
which  might  further  potentiate  AHR,  perhaps  by
direct  effects  on  inflammatory  cells  (e.g.  eosino-
phils)  or  by  stimulating  cytokine  release  from cells
in the nasal mucosa, a process which occurs in the
human nasal airway.99
Alternatively, neuropeptides  may not just  upregu-
late  the  inflammation  resulting  in  AHR,  but  also
directly  cause  the  increased  response  observed  in
AHR. A  number of stimuli, including antigen, cause
neuropeptide  release  in  the  human nasal  airway.  If
tachykinin  activity  is potentiated, due to more neu-
ropeptide  release  or  inhibition  of  metabolism,  this
would  cause  an  increase  in  neuropeptide-mediated
symptoms  such  as  nasal  obstruction  and  rhinor-
rhoea:  in  effect  the  ‘hyper’-response  observed  in
AHR.  Phosphoramidon,  a  NEP  inhibitor,  can  cause
AHR  in  the  lower  airways  of  guinea  pigs100 and
man,101 and  potentiates  the  activity  of  neuropep-
tides in the human nasal airway.102 NEP is present in
the human nasal mucosa,103 and correlates with the
presence  of  nasal  AHR.27 Epithelial  damage  may
cause  AHR  by  reducing  the  activity  of  NEP  asso-
ciated  with airway epithelial  cells.  However, in  the
human  nasal  airway,  PAF-induced AHR  is  not  asso-
ciated  with  the  release  of  sub  P  (Fig.  2).  PAF  may
cause AHR by a different mechanism to antigen, the
former  being  independent  of  neuropeptide  release.
Alternatively,  PAF  may  potentiate  subsequent  neu-
ropeptide  release  from  sensory  nerves,  and  not
cause neuropeptide release per se, so an increase in
sub P would only occur in the presence of a further
stimulus,  such as  histamine.
It is unknown which particular neuropeptides may
be involved in the development of AHR. Sub P is the
most  potent  endogenous  mediator  at  the  NK-1
receptor,  but  it  does  not  induce AHR  in  the  lower
airways of sheep, while NK-A does.104 In the human
nasal  airway,  NK-1  receptors  are  localised  to  the
epithelium,  glands  and  blood  vessels,  while  NK-2
receptors are limited to arterial vessels.105 This is in
agreement with the findings that nasal obstruction is
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extravasation probably involves both NK-1 and NK-2
receptor activation,106 and would explain the incon-
sistency  that  NK-1  or  NK-2  receptor  antagonists
prevent AHR  in  some  studies  but  not  in  others.  In
chronic asthma, both receptor subtypes are upregu-
lated,107 and  this  may  happen  in  chronic  allergic
rhinitis as well. There are no reports investigating the
role of CGRP in AHR.
Cytokines
Cytokines are intercellular messenger peptides which
are  released  by  a  variety  of  cells  to  influence  the
activity  of  other  cells. Three  cytokines  are  of  vital
importance  in  the  development  and  regulation  of
eosinophil function: the interleukins IL-3 and IL-5, and
granulocyte-macrophage  colony-stimulating  factor
(GM-CSF). All three prevent apoptosis and prolong the
survival of eosinophils in vitro, and in particular, IL-5
is essential for the differentiation of progenitor cells
into eosinophils.108
Both  IL-4  and  IL-5  have  been  implicated  in  the
development  of  AHR.109 In  animals,  IL-5  causes  a
marked eosinophilia, eosinophil activation and AHR.91
Monoclonal antibodies to IL-5 abolish antigen-induced
eosinophilia  and  AHR  in  the  lower  airway  of  the
guinea  pig.110 IL-4  regulates  the  activity  of  CD4+
T-lymphocytes,  which  release  a  range  of  cytokines
capable of priming and activating eosinophils,71 and
can also activate neutrophils.111 Furthermore, mem-
ory T-cells in the nasal mucosa of patients with nasal
allergy  can  produce  IL-4  during  allergen  exposure,
which may upregulate the inflammatory response.112
Patients  with  SAR  or  PAR  have  a  raised  number  of
CD4+ T-cells.113
Following nasal allergen challenge, the levels of IL-
1a ,  IL-1b ,  IL-5,  IL-6,  IL-8  and  GM-CSF  are  raised  in
nasal  secretions,114–116 and  human  eosinophils  are
potential  sources  of  these  cytokines.117 Epithelial
cells,  isolated  from  allergic  rhinitics,  showed
increased immunostaining for GM-CSF, IL-8, the recep-
tors for IL-1 and TNF-a ,118 and also they release more
IL-1b , IL-8, GM-CSF and TNF-a compared to epithelial
cells from non-allergic subjects.119 Similar increases in
IL-4-, IL-5- and GM-CSF-positive cells are observed in
biopsies from the  nasal  mucosa  of atopics.120 Both
interferon-g and TNF-a (and possibly other cytokines)
cause  an  upregulation  of  ICAM-1  on  human  nasal
epithelial cells,121 while IL-4 upregulates the expres-
sion of VCAM-1.113 Both these adhesion molecule are
upregulated in allergic rhinitis.113
Cytokines may promote AHR by upregulating the
recruitment  and  activation  of  eosinophils  (Fig.  3)
and neutrophils. For example, there are close corre-
lations between the number of eosinophils and GM-
CSF  levels  in  bronchoalveolar  fluid  (BALF)  from
subjects  with asthma,122 while  the  survival of  eosi-
nophils  in  BALF  from subjects with allergic rhinitis
correlates  the  concentrations  of  IL-5  and  GM-CSF
present.123 Neurokinin  NK-2  receptor  antagonists
inhibit AHR  induced  by  IL-5  in  the  guinea  pig,  but
not  the  associated  eosinophilia,124 indicating  that
cytokines are involved in cell recruitment, following
which  various mediators  are released, such as  neu-
ropeptides  which  may  cause  the  development  of
AHR. IL-1 may also be involved in the development
of AHR,125 but it has a wide range of cellular actions,
so it is difficult to suggest a precise role for it in the
pathogenesis of AHR. Interestingly, it may inhibit the
activity  of  NEP,126 or  induce  the  generation  of
oxygen-based  free  radicals  from  macrophages  and
neutrophils.127
Finally,  glucocorticoids downregulate the produc-
tion of IL-3 and IL-5 following allergen challenge; this
effect  may  contribute  to  the  action  of  steroids  in
abolishing  AHR,116 although  glucocorticoids  have
other actions too.
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FIG.  2.  The  effect  of  PAF  on  the  concentration  of  substance  P
in  nasal  lavage  fluid.  The  nasal  airway  was  challenged  with
either  saline  or  PAF,  60m g,  and  the  airway  was  lavaged  2,  4
and 6h after challenge. Following lavage, a peptidase
inhibitor  was  added  to  prevent  degradation  of  substance  P
prior  to  assay.  Data  are  means± SEM  from  nine  subjects.
FIG. 3. Role of cytokines in the modulation of eosinophil
function  in  allergy.
71Chemokines
Chemokines are cytokines which possess chemotactic
activity,  and  are  divided  into  groups  depending  on
their structure. The two main groups are CC chem-
okines, where two cysteine residues are adjacent to
each other (e.g. RANTES, MIP-1a , eotaxin) and CXC
chemokines, in which the two cysteine residues are
separated  by  a  third  amino  acid  (e.g.  IL-8).  Some
chemokines (RANTES, eotaxin) appear to be selective
for eosinophils, while IL-8 has a chemotactic activity
only for neutrophils (though there are reports that it
also has an action on primed human eosinophils).128
The levels of RANTES,115,129 MIP-1a ,115 eotaxin130
and  IL-8115,131 detected  in  nasal  lavage  are  raised
following nasal allergen challenge in man. Treatment
with  glucocorticoids,  which  inhibits  inflammatory
cell  recruitment,  abrogates  these  increases.115,132
Interestingly, mucosal cells obtained from the noses
of  subjects  with  allergic  rhinitis  show  increased
expression of mRNA for RANTES129 and eotaxin.130 It
is now generally accepted that RANTES and eotaxin
are  important  in  IL-5-mediated  eosinophilia,  where
the latter causes the mobilisation of eosinophils into
the circulation while the local release of chemokines
provides a ‘homing’ mechansim for the migration of
eosinophils into the tissues.128 However, no study has
yet investigated the specific roles of chemokines in
nasal hyperresponsiveness. Notwithstanding, admin-
istration of RANTES into the nasal airway of subjects
with allergic rhinitis causes an eosinophilia but not an
influx of other inflammatory cells.133 However, the
same study also found that, after allergen challenge,
administration  of  RANTES  also  caused  an  influx  of
basophils, neutrophils, lymphocytes and monocytes,
as  well  as  causing  epithelial  shedding,  a  response
similar to that observed in nasal hyperresponsiveness.
It is therefore likely that chemokines have an impor-
tant role in the recruitment of inflammatory cells that
is  observed  during  the  development  of  nasal
hyperresponsiveness.
Nitric  oxide
Recently, a large amount of research has been carried
out on the role of nitric oxide in airway disease. There
is evidence that nitric oxide synthase (NOS) activity is
increased  in  PAR134 and  in  SAR.135,136 This  would
increase the amount of nitric oxide available to react
with superoxide, generating free radicals which may
contribute to the development of AHR.33 Nitric oxide
may also have a role in the production of cytokines
necessary for eosinophil survival, such as IL-4 and IL-
5.137 Therefore, one might expect inhibitors of NOS
to  prevent  AHR,  either  by  reducing  free  radical
production or via the induction of eosinophil apopto-
sis. Paradoxically, NOS inhibitors actually induce AHR
to histamine and bradykinin in both the human nasal
airway138 (Fig. 4) and lower airways of asthmatics,139
and also in animal models.140 It is possible that in the
normal,  non-inflamed  airway,  nitric  oxide  is  pro-
tective, so inhibitors of NOS would cause AHR, but in
chronic  airway  inflammation,  an  inappropriate
degree of nitric oxide production may be harmful and
potentiate the allergic response.
Interestingly,  NO  is  thought  to  be  the  central
mediator of inhibitory NANC transmission. Therefore,
inhibition  of  NOS  may  cause  a  reduction  in  the
activity  of  inhibitory  NANC  nerves,  which  could
cause AHR by potentiating neurogenic inflammation
mediated  by  excitatory  NANC  nerves.  In  chronic
allergy, excessive NO production could cause AHR by
the formation of the peroxynitrite free radical, which
causes AHR  in  the  guinea  pig  airway,  possibly  by
inhibiting  cGMP  production.33 Furthermore,  other
NO  metabolites,  such  as  nitryl  chloride,  can  be
synthesised  by  neutrophils,  inactivating  endothelial
cell angiotensin-converting enzyme.141 This enzyme is
involved  in  the  degradation  of  kinins  and  possibly
tachykinins in allergic rhinitis,102,142 so inhibition of
this enzyme may influence AHR by potentiating the
action of these mediators.
Kinins
A number of studies have identified a role for kinins in
the development of AHR in the lower airways of both
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FIG. 4. The percentage decrease in the minimal cross-
sectional area of the nasal airway (Amin) from baseline
10min after challenge with histamine, 200m g. The nasal
cavity was pretreated every 30min with saline, a NOS
inhibitor  (L-NAME  or  L-NMMA,  1m mol),  or  L-NAME  together
with L-arginine, 30m mol, for 6h prior to the histamine
challenge.  Data  are  means± SEM  from  10  subjects.  **,*Sig-
nificant  increase  in  the  histamine-induced  percentage
change  in  Amin following  pretreatment  with  a  NOS  inhibitor
compared to saline pretreatment (*,**P<0.05 and P<0.01,
respectively,  Wilcoxon  sign-rank  test).the  guinea  pig143 and  sheep.144 Furthermore,  the
ability  of  MBP  and  synthetic  cationic  proteins  to
induce AHR in the lower airways of rats is dependent
on  the  generation  of  kinins.46 In  all  three  studies,
administration of a bradykinin B2 receptor antagonist
inhibited  the  development  of  AHR,  and,  where
investigated, also appeared to have an effect on the
recruitment of eosinophils into the airway. ECP can
stimulate  kallikrein  activity  in  vitro,145 resulting  in
kinin production, so eosinophil-derived cationic pro-
teins may generate kinins which lead to AHR.
Recent investigations have found that AHR in the
human  nasal  airway  may  also  be  kinin  dependent.
Icatibant, a highly potent antagonist at the bradykinin
B2 receptor, prevents PAF-induced AHR (Fig. 5), while
PAF causes an increase in the level of kinins in nasal
lavage fluid (Fig. 6). Kinins are produced in both PAR
and SAR, and could therefore contribute to AHR in
allergic rhinitis.
One important consideration is the source of the
kinins. In SAR, antigen challenge causes an increase in
plasma extravasation, so the kinins detected may be a
product of plasma kallikrein activity. However, antigen
does not induce plasma extravasection in PAR,5 and
the role of plasma kallikrein has not been assessed in
either allergic rhinitis or asthma.146The levels of tissue
kallikrein in nasal secretions are increased in allergic
rhinitis,147 but it is not thought that tissue kallikrein
can  be  activated  by  cationic  proteins.46 A  novel
solution  to  this  anomaly  is  as  follows.  Neutrophils
contain  tissue kallikrein  and bind  plasma kallikrein,
together with high- and low-molecular weight kinino-
gen,  on  the  cell  surface.148,149 Antigen  and  PAF
challenge cause a neutrophilia in addition to eosino-
phil recruitment,54 therefore neutrophils may provide
the components needed for the generation of kinins.
The  mechanism  by  which  kinins  induce  AHR
remains unknown. Exogenous kinins applied to the
airways do not cause AHR in animal models46 nor in
the human nasal airways (Turner & Foreman, unpub-
lished data), though one study found that bradykinin
can produce AHR to acetylcholine in the guinea pig
airway.150 Bradykinin causes sensitisation of C-fibres
in  the  guinea  pig  trachea,151 and  there  is evidence
that in the human nose enhanced responsiveness to
bradykinin is mediated by neural reflexes.15 Bradyki-
nin can also release sub P and other neuropeptides
from sensory nerve  endings,98,152 so it  may  induce
AHR by a neuropeptide-dependent mechanism. How-
ever, although administration of PAF into the human
nose causes kinin generation, there is no increase in
sub P release. Alternatively, bradykinin can initiate the
production  of  the  cytokines  IL-1,  IL-6  and  IL-8  in
vivo 153 and stimulate the release of TNFa /b and IL-1
from macrophages.154 These cytokines may contrib-
ute to AHR as previously mentioned. Interestingly, the
eosinophilia  induced  by  antigen  challenge  in  the
lower  airway  of  the  guinea  pig  is  reduced  by
bradykinin receptor antagonists143 or an inhibitor of
tissue kallikrein,155 thus  providing evidence for the
involvement  of kinins in  the recruitment  of eosino-
phils following exposure to allergen.
Nasal airway hyperresponsiveness
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FIG. 5. The percentage decrease in the minimal cross-
sectional area of the nasal airway (Amin) from baseline
10min after challenge with histamine, 200m g. The nasal
cavity was pretreated with saline (Sal), icatibant (Icat),
200m g, and/or PAF, 60m g, 6h prior to the histamine chal-
lenge. Data are means± SEM from 15 subjects. **,
+Sig-
nificant increase in the histamine- induced percentage
change  in  Amin following  saline/PAF  pretreatment  compared
to pretreatment  with  saline  only  (**P<0.01,  Wilcoxon  sign-
rank test) or icatibant/PAF (
+P<0.05, Wilcoxon sign-rank
test).
FIG. 6.  The effect of PAF on the  concentration of kinins in
nasal lavage fluid. The nasal airway was challenged with
either  saline  or  PAF,  60m g,  and  the  airway  was  lavaged  2,  4
and 6h after challenge. Data are means± SEM from 13
subjects. *Significant increase (P<0.05) in levels of kinin
following  challenge  with  PAF  compared  to  saline  (Wilcoxon
sign-rank  test).The  role  of  inflammatory  cells  in
hyperresponsiveness
From the  evidence  presented, it  might  appear  that
eosinophils have a vital  role in the development  of
AHR. However, the relationship between eosinophil
activation and AHR remains controversial. Certainly,
eosinophils are involved in the late response, but the
development of AHR may not be dependent on the
presence of eosinophils. Studies conducted in animal
models  indicate  that  AHR  can  occur  without  a
detectable  eosinophilia,  and  vice  versa.156 Data
obtained  from  studies  in  the  human  nose  similarly
imply that AHR does not necessarily occur together
with  eosinophil  activation,48,49 while  antigen  can
induce an eosinophilia without causing AHR.157 There
are a range of airway inflammatory conditions which
feature an eosinophilic infiltration, but no associated
AHR.22 Nonetheless,  the  close  association  between
eosinophil recruitment, activation and AHR in many
studies35,52,67 implies, at the very least, that eosino-
phils may contribute to the development of AHR.
Although eosinophils are the main cells which have
been implicated in the mechanism underlying AHR, it
is  likely  that  other  cells  are  involved,  including
neutrophils, T-lymphocytes, macrophages, B-cells and
basophils.71 Basophils, which may be involved in the
late  allergic  response,  are  capable  of  generating
histamine, bradykinin, MBP, LTC4, IL-4 and IL-8,71,158
which may contribute to AHR. Macrophages may also
be involved in the development of nasal AHR, possibly
by generating cytokines and free radicals.159
The involvement of the neutrophil in AHR is often
overlooked, yet there is a wealth of evidence for an
active  role.  Not  only  may  they  contribute  to  the
generation of kinins and cause tissue damage via the
superoxide  burst,  but  they  also  generate  PAF ,  LTB4
and a variety of cytokines. It is interesting to note that
ECP  has now been detected in neutrophils.160 Neu-
trophils  isolated  from  atopic  subjects  have  an
increased capacity for myeloperoxidase release, and
this  enzyme  can  generate  nitric  oxide-derived  oxi-
dants, which can induce AHR and inhibit kininase II,
an  enzyme  responsible  for  the  metabolism  of
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FIG.  7.  Putative  mechanism  for  the  development  of  airway  hyperresponsiveness.kinins.141 The hypothesis that both neutrophils and
eosinophils act together in causing AHR is one which
warrants further investigation.
The upregulation of ICAM-1 and VCAM-1 by cyto-
kines in allergic rhinitis has already been discussed.
ICAM-1  and  VCAM-1,  present  on  endothelial  cells,
bind  respectively to integrins LFA-1 (a Lb 2 integrin)
and VLA-4  (a 4b 1  integrin)  on  leukocytes,  allowing
leukocytes  to  adhere  to  the  endothelium  prior  to
migration. The interaction between VCAM-1 and VLA-
4 appears to be particularly important in eosinophil
migration,  as  neutrophils  do  not  have  the  VLA-4
receptor  on  their  surface.161 Interfering  with  the
VCAM-1/VLA-4 pathway may, therefore, prevent eosi-
nophil-dependent  hyperresponsiveness.  Monoclonal
antibodies  (mAbs)  to  the  integrin  sub-unit  a 4  have
been  developed  which  abolish  antigen-induced
hyperresponsiveness in the lower airways of a num-
ber of animal models of airway allergy.162 –164 Inter-
estingly, this effect was not always associated with an
decrease  in  the  airway  eosinophilia,163,165 possibly
because  other  mechanisms  exist  (e.g.  via  ICAM-1)
whereby  eosinophil  migration  may  occur.  Further
development  of  these mAbs  may  provide  a  useful
therapeutic intervention for airway allergy in man.
Summary
It  would  appear  that  a  number  of  mediators  are
capable of inducing AHR in the human nasal airway,
perhaps  acting  via  different  mechanisms,  which
would help explain the conflicting evidence regard-
ing a role for eosinophils or airway epithelial damage
in this process. However, the fact that inhibitors of
leukotrienes,  PAF,  kinins  and  tachykinins  can  all
inhibit antigen-induced AHR implies that there may be
a  central  common  pathway  in  the  pathogenesis  of
AHR. Since neurogenic inflammation can potentially
be  modulated  by  all  of  these  mediators,  neuropep-
tides  may  be  involved  in  the  final  stage  of  AHR
induction, perhaps as shown in Fig. 7. Antagonists of
these mediators appear to inhibit the development of
hyperresponsiveness in animals, and the development
of similar antagonists for use in man may provide new
pharmacological treatments for allergic rhinitis, and
perhaps for other allergic airway diseases as well.
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